Napier Healthcare Deploys Hospital Information Management System at Bhutan’s Apex Healthcare Institution
The Jigme Dorji Wangchuck National Referral Hospital (JDWNRH) adopts Napier's flagship web-based product to improve patient management, better track consistency in clinical outcomes and enhance overall quality of healthcare.
Singapore, Thursday, January 17, 2013 -- (Business Wire India) -- Napier Healthcare's Hospital Information Management System (HIMS) has been successfully implemented at the Jigme Dorji Wangchuck National Referral Hospital (JDWNRH) in Bhutan.
Bayer Submits VEGF Trap-Eye (aflibercept) for Treatment of Macular Edema Following Central Retinal Vein...
Berlin, January 7, 2013 – Bayer HealthCare today announced that Bayer Yakuhin, Ltd., Osaka, Japan, has submitted an application for marketing authorization for VEGF Trap-Eye (aflibercept solution for injection) for the treatment of macular edema following Central Retinal Vein Occlusion (CRVO) to the Ministry of Health, Labour and Welfare (MHLW) in Japan.
The submission of VEGF Trap-Eye for macular edema following CRVO is based on data from the Phase III COPERNICUS and GALILEO studies. In both studies, the primary efficacy endpoint was the proportion of patients who gained at least 15 letters – measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) eye chart – of Best Corrected Visual Acuity (BCVA) at 24 weeks compared to baseline on the ETDRS visual acuity charts. The VEGF Trap-Eye 2 milligrams monthly group was significantly superior to the sham control group for the primary endpoint. The effects were largely maintained in the follow-up phase until week 52.
AstraZeneca Pharma India Limited (AZPIL) today announced the launch of a new patented antiplatelet drug BRILINTA® (Ticagrelor) in India. BRILINTA® is an oral antiplatelet treatment for Acute Coronary Syndromes (ACS) in adult patients. BRILINTA® is competitively priced to enable ACS patients benefit from having access to this medicine.
BRILINTA® works by preventing the formation of new blood clots and maintaining blood flow in the body to help reduce patient’s risk of another cardiovascular event (called atherothrombotic events) such as a heart attack or cardiovascular death.